A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D004341:Drug Evaluation; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005819:Genetic Markers; D005822:Genetic Vectors; D006801:Humans; D007258:Informed Consent; D019868:Kanamycin Kinase; D009355:Neomycin / Q000494:pharmacology; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010770:Phosphotransferases / Q000235:genetics*; D011994:Recombinant Proteins / Q000235:genetics; D012107:Research Design; D014161:Transduction, Genetic; D014182:Transplantation, Autologous
D005819:Genetic Markers; D011994:Recombinant Proteins; D005047:Etoposide; D016190:Carboplatin; D010770:Phosphotransferases; D019868:Kanamycin Kinase; D009355:Neomycin